Completed PHASE2 INTERVENTIONAL 2-arm NCT06390748

Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes

Investigating the Immunomodulatory Effects of Esmolol in Sepsis Management and Its Impact on Patient Outcomes

Sponsor: Lin Chen

Conditions Beta-Blocker Catecholamine; Overproduction Cytokine Storm Immunologic Paralysis Lymphocyte Disorder T Sepsis Sympathetic Nervous System Diseases

Interventions esmolol

Updated 4 times since 2024 Last updated: May 25, 2024 Started: Jan 1, 2021 Primary completion: Dec 31, 2023 Completion: Dec 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Beta-Blocker and Catecholamine; Overproduction, this trial is completed. The trial is conducted by Lin Chen and has accumulated 4 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jun 2024 — Jul 2024 [monthly]

Completed PHASE2
May 2024 — Jun 2024 [monthly]

Completed PHASE2

First recorded

Jan 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Lin Chen

Data source: Sichuan Provincial People's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chengdu, China